Loading...
XJPX
4593
Market cap277mUSD
Dec 05, Last price  
425.00JPY
1D
3.41%
1Q
-21.73%
Jan 2017
-80.40%
IPO
-71.67%
Name

Healios KK

Chart & Performance

D1W1MN
XJPX:4593 chart
P/E
—
P/S
76.84
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.03%
Rev. gr., 5y
44.46%
Revenues
560m
+362.81%
279,997,00098,167,00077,640,00027,666,000089,000,00027,000,00041,000,00090,000,000121,000,000560,000,000
Net income
-4.24b
L+10.78%
-477,258,000-958,103,000-3,433,554,000-1,776,653,000-5,097,000,000-4,409,000,000-5,513,000,000-4,912,000,000-5,170,000,000-3,823,000,000-4,235,000,000
CFO
-1.82b
L-35.61%
0-167,172,000-3,782,678,000-1,762,184,000-5,148,000,000-4,970,000,000-3,945,000,000-5,089,000,000-4,601,000,000-2,822,000,000-1,817,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
URL
https://www.healios.co.jp/
IPO date
Jun 16, 2015
Employees
71
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT